Previous 10 | Next 10 |
Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...
Rhythm Pharmaceuticals ( NASDAQ: RYTM ) stock rose ~20% on July 20 after its drug Imcivree was granted early access authorization in France for patients with genetically-confirmed Bardet-Biedl syndrome (BBS) to treat obesity and control of hunger. The company said t...
-- Reimbursed early access program allows for patients in France to receive setmelanotide for treatment of obesity and control of hunger associated with BBS -- BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical...
Gainers: Inotiv ( NOTV ) +18% . IO Biotech ( IOBT ) +16% . SOPHiA GENETICS ( SOPH ) +10% . Apyx Medical ( APYX ) +9% . Rhythm Pharmaceuticals ( RYTM ) +9% . Losers: Regulus Therapeutics ( RGLS ) -14% . Aerovate...
The commercial stage biotech Rhythm Pharmaceuticals ( NASDAQ: RYTM ) added 7% in the pre-market Monday after the company announced that the U.K.’s National Institute for Health and Care Excellence (NICE) recommended its weight loss therapy Imcivree (setmelanotide). ...
- IMCIVREE will be funded and available for use within 90 days in the National Health Service - BOSTON, July 18, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
The shares of commercial stage biotech Rhythm Pharmaceuticals ( NASDAQ: RYTM ) rose sharply for the second straight session on Wednesday to approach the highest level since mid-April as Wall Street reacts to the company’s Phase 2 data for setmelanotide in hypothalamic o...
Gainers: XORTX Therapeutics ( XRTX ) +39% . Gossamer Bio ( GOSS ) +24% . Rhythm Pharmaceuticals ( RYTM ) +23% . Apollo Endosurgery ( APEN ) +18% . Tyra Biosciences ( TYRA ) +15% . Losers: Humanigen ( HGEN ) -80% . Atara Biotherap...
Humanigen HGEN -68% as trial for COVID-19 therapy fails . Atara Biotherapeutics ATRA -46% on interim analysis of phase 2 study for multiple sclerosis candidate. TherapeuticsMD TXMD -41% as merger agreement ends . Helius Medical Technologies ( HSDT...
Rhythm Pharmaceuticals ( NASDAQ: RYTM ) said its medicine setmelanotide helped reduce Body Mass Index (BMI) in patients with severe obesity and hyperphagia (excessive hunger) in people living with hypothalamic obesity as per interim data from a phase 2 trial. H...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...